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Known modiﬁable risk factors account for a small fraction of premenopausal breast cancers. We investigated associations between
pre-diagnostic circulating amino acid and amino acid-related metabolites (N = 207) and risk of breast cancer among predominantly
premenopausal women of the Nurses’ Health Study II using conditional logistic regression (1057 cases, 1057 controls) and
multivariable analyses evaluating all metabolites jointly. Eleven metabolites were associated with breast cancer risk (q-value < 0.2).
Seven metabolites remained associated after adjustment for established risk factors (p-value < 0.05) and were selected by at least
one multivariable modeling approach: higher levels of 2-aminohippuric acid, kynurenic acid, piperine (all three with q-value < 0.2),
DMGV and phenylacetylglutamine were associated with lower breast cancer risk (e.g., piperine: ORadjusted (95%CI) = 0.84
(0.77–0.92)) while higher levels of creatine and C40:7 phosphatidylethanolamine (PE) plasmalogen were associated with increased
breast cancer risk (e.g., C40:7 PE plasmalogen: ORadjusted (95%CI) = 1.11 (1.01–1.22)). Five amino acids and amino acid-related
metabolites (2-aminohippuric acid, DMGV, kynurenic acid, phenylacetylglutamine, and piperine) were inversely associated, while
one amino acid and a phospholipid (creatine and C40:7 PE plasmalogen) were positively associated with breast cancer risk among
predominately premenopausal women, independent of established breast cancer risk factors.
npj Breast Cancer (2021)7:54 ; https://doi.org/10.1038/s41523-021-00262-4

INTRODUCTION
Breast cancer is the most common malignancy among women in
the United States, with more than 250,000 cases diagnosed each
year1. Known modiﬁable risk factors are estimated to account for
only around one-third of postmenopausal breast cancers2–4, and
an even smaller fraction of premenopausal cancers2,5. Thus, new
strategies are needed for the identiﬁcation of modiﬁable risk
factors, especially for premenopausal breast cancers.
Metabolites are small molecules that are produced and
consumed by cellular metabolism. The study of the complete
collection of metabolites, called metabolomics, provides a direct
signature of cellular activity in the body and has emerged as a
powerful tool for the diagnosis, characterization, and prediction of
disease. Metabolomic methods have uncovered biomarkers for a
wide variety of cancers including colorectal, gastric, pancreatic,
liver, ovarian, breast, urinary, esophageal, and lung6. In breast
cancer, metabolomics has proven useful for tumor biology
characterization, predicting treatment response, anticipating
recurrence, and estimating prognosis7.
More recently, prospective epidemiological studies have used
metabolomics to identify metabolite risk factors for several
cancers including pancreatic8–10, prostate11,12, liver13, colorectal14,
ovarian15,16, endometrial17, and breast cancer18–22. For breast
cancer, studies have used both targeted18,21,23 and untargeted20,22
methods to discover metabolomic risk factors associated with
diet20,23, body mass index (BMI)21, microbiota metabolism20, lipid,
amino acid, and other metabolic pathways18,20,22. While several
studies stratiﬁed results by estrogen receptor (ER) status18,21,23, no

prospective metabolomic breast cancer studies have investigated
differential effects by menopausal status.
In this study, we assessed the association of over 200
prospectively measured circulating amino acid and amino acidrelated metabolites with risk of breast cancer among the
predominantly premenopausal women (1057 cases and 1057
matched controls) of the Nurses’ Health Study II (NHSII).

RESULTS
Study population
1057 cases and 1057 matched controls were included in this study
(Table 1). Women were an average 53 years old and predominantly premenopausal (80%) at the time of blood collection. At
diagnosis, 42% of the women were premenopausal and 46% were
postmenopausal. The mean time between blood collection and
diagnosis was 8 years (SD = 4.4), ranging from 10 months to 17.4
years. (1st quartile: 4.25 years; 3rd quartile: 11.6 years).
Conditional logistic regression (CLR)
Eleven metabolites were signiﬁcantly associated with risk of breast
cancer based on the simple model (Fig. 1 and Supplementary
Table 1). Six metabolites were associated with lower risk while ﬁve
metabolites were associated with higher risk of overall breast
cancer. Dimethylguanidino valeric acid (DMGV; OR per 1-SD
increase (95% CI) = 0.84 (0.77–0.92)), 2-aminohippuric acid (OR
(95% CI) = 0.84 (0.76–0.92)), and piperine (OR (95% CI) = 0.85
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Table 1.

Characteristics of breast cancer cases and matched controls
at blood collection in the Nurses’ Health Study II, mean (SD) or %.
Cases
(n = 1057)

Controls
(n = 1057)

Age at blood collectiona (y)

44.7 (4.5)

44.8 (4.4)

Age at menarche (y)

12.4 (1.3)

12.8 (1.4)

Time between sample collection
and diagnosis (y)

8.0 (4.4)

1234567890():,;

Parity and age at ﬁrst birth (%):
Nulliparous

21.1

15.9

1–2 children, ≥25 y
1–2 children, <25 y

39.2
14.7

34.9
15.9

3+ children, <25 y

11.3

16.6

3+ children, ≥25 y

13.8

14.2

Ever breastfed (%)

63.1

65.0

Family history of breast cancer (%)

17.4

10.8

Personal history of benign breast
disease (%)

22.1

15.6

BMI at age 18 (kg/m2)

20.8 (2.9)

21.1 (3.1)

Weight change between age 18
and blood collection (kg)

11.6 (12.0)

12.6 (13.2)

Physical activity, MET-h/wk

18.0 (15.3)

18.1 (15.5)

Alcohol consumption (g/day)
Past/current exogenous hormone
useb (%)

3.8 (6.9)
86.3

3.3 (5.6)
86.7

Menopausal status at blood collectiona (%)
Premenopausal
80.2

79.7

Postmenopausal

12.7

13.1

Unknown

7.1

7.3

Menopausal status at diagnosisa (%)
Premenopausal

42.0

42.2

Postmenopausal

46.4

47.1

Unknown

11.6

10.7

97.2
68.7

98.4
74.7

Caucasiana (%)
Fasting (>8 h) at blood
collectiona (%)
a

Matching factor
Oral contraceptive or menopausal hormone therapy

b

(0.78–0.93)) had the strongest inverse associations. C40:7 phosphatidylethanolamine (PE) plasmalogen (OR (95% CI) = 1.14
(1.05–1.25)) and asparagine (OR (95% CI) = 1.14 (1.04–1.26)) had
the strongest positive associations. Creatine was the only
metabolite with q-value > 0.2 in the simple model but is included
here as q-value < 0.2 in both Lasso models. Results were similar
when we included adjustment for breast cancer risk factors
(DMGV: 0.88 (0.79–0.97); 2-aminohippuric acid: 0.85 (0.77–0.93);
C40:7 PE: plasmalogen: 1.11 (1.01–1.22); asparagine: 1.10
(1.00–1.22)) and when we restricted to premenopausal women
(Fig. 1 and Supplementary Table 2) or ER+ tumors (Fig. 1 and
Supplementary Table 3).
Among the 11 selected metabolites, only DMGV showed effect
modiﬁcation by BMI with stronger associations among women
with high BMI (adjusted model, high BMI: OR (95% CI) = 0.82
(0.70–0.97); normal BMI: OR (95% CI) = 0.94 (0.83–1.06);
p-interaction = 0.04). Signiﬁcant interactions with BMI were
observed for several additional metabolites that were not
signiﬁcant overall; for example C36:4 DAG/TAG fragment (high
BMI: OR (95% CI) = 0.92 (0.80–1.06); normal BMI: OR (95% CI) =
1.21 (1.06–1.37); p-interaction = 0.005), serine (high BMI: OR (95%
npj Breast Cancer (2021) 54

CI) = 1.19 (1.04–1.38); normal BMI: OR (95% CI) = 0.93 (0.83–1.05);
p-interaction = 0.008), and proline betaine (high BMI: OR (95%
CI) = 0.82 (0.72–0.94); normal BMI: OR (95% CI) = 1.04 (0.92–1.17);
p-interaction = 0.017).
Of the 11 selected metabolites, we only observed stronger
associations with risk of ER- tumors in the adjusted model (ER−;
Supplementary Table 3) for asparagine (ER− tumors: OR (95% CI)
= 1.21 (0.99–1.47); ER+ tumors: OR (95% CI) = 1.06 (0.94–1.18); pheterogeneity = 0.03). Three additional metabolites were suggestively different by ER status: betaine (ER− tumors: OR (95% CI) =
0.89 (0.73–1.09); ER+ tumors: OR (95% CI) = 1.07 (0.96–1.20);
p-heterogeneity = 0.02), 4-acetamidobutanate (ER− tumors: OR
(95% CI) = 0.89 (0.72–1.09); ER+ tumors: OR (95% CI) = 0.97
(0.87–1.08); p-heterogeneity = 0.03), and histidine (ER− tumors:
OR (95% CI) = 1.06 (0.87–1.29); ER+ tumors: OR (95% CI) = 1.01
(0.91–1.13); p-heterogeneity = 0.05).
In an exploratory analysis including metabolites with >10%
missing values (N = 19; four metabolites had >90% missingness),
metoprolol (45% missing values) was nominally signiﬁcantly
associated with risk of breast cancer (likelihood-ratio test pvalue = 0.04; data not shown). Women with detectable metoprolol
levels had a 23% higher risk (presence–absence indicator p-value
= 0.07) of breast cancer compared to women with undetectable
metoprolol. However, among women with measured metoprolol,
higher levels were associated with lower risk (OR per one unit
increase in log-transformed and standardized metabolite levels =
0.91, p-value = 0.14). The remaining metabolites with high
missingness were not associated with risk of breast cancer.
Multivariable models of the joint association of all
metabolites
The inverse association of piperine with risk of breast cancer met
the threshold for statistical signiﬁcance (p-value < 0.05 and q-value
< 0.20) in all three simple (without adjustment for risk factors)
multivariable models, Lasso, Elastic Net, and Random Forests
(Tables 2 and 3). In addition, DMGV and N2,N2-dimethylguanosine
were detected in the Random Forests model with minimal
adjustment, satisfying a q-value threshold of 0.05. Higher levels
of C40:7 PE plasmalogen and creatine were associated with
increased breast cancer risk in CLR Lasso models (q-value < 0.20).
These associations remained signiﬁcant after further adjustment
for risk factors (nominal p < 0.05) with the exception of N2,N2dimethylguanosine in Random Forests (p = 0.05) and piperine in
Elastic Net (nominal p-value < 0.05, q-value > 0.2).
When all eleven identiﬁed metabolites were assessed together
in an adjusted lasso CLR model, ten metabolites remained
independently associated with risk of breast cancer. The direction
of association in the lasso CLR model was consistent with the
previous CLR and multivariable models except for N2,N2dimethylguanosine who’s coefﬁcient was estimated to be equal
to zero, reﬂecting its high correlation with kynurenic acid and 2aminohippuric acid (Fig. 2).
DISCUSSION
We conducted a large-scale study of 207 circulating amino acid
and amino acid-related metabolites, and risk of breast cancer in a
nested case-control study (1057 cases and 1057 matched controls)
within NHSII, a cohort of predominantly premenopausal women.
Higher levels of six metabolites, 2-aminohippuric acid, DMGV,
kynurenic acid, N2, N2-dimethylguanosine, phenylacetyl glutamine, and piperine, were associated with lower breast cancer risk
while higher levels of asparagine, creatine, and three lipids, C20:1
LPC, C34:3 PC plasmalogen, C40:7 PE plasmalogen, were
associated with increased breast cancer risk. Inverse associations
between 2-aminohippuric acid, DMGV, kynurenic acid, phenylacetyl glutamine and piperine, and the positive associations with
Published in partnership with the Breast Cancer Research Foundation
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Fig. 1 Odds ratios and 95% conﬁdence intervals (CI) per 1 SD increase for metabolites signiﬁcantly associated with risk of overall breast
cancer (p-value < 0.05 and q-value < 0.2) in Nurses’ Health Study II, among premenopausal women only, by BMI category (<25, ≥25)***,
and by ER status (ER positive, ER negative)****. Creatine, although not selected by the conditional logistic regression (p-value < 0.05, q-value
> 0.2), is shown here for completeness, as is was selected by the multivariable models. *Simple model: adjusts for matching factors including
menopause status at blood draw, time of blood draw, date/season of blood draw, luteal day at blood draw, fasting status at blood draw,
menopausal status at diagnosis and race. **Adjusted model: in addition to matching factors, this model adjusts for BMI at age 18, weight
change between age 18 and time of blood draw, age at menarche, parity and age at ﬁrst birth, family history of breast cancer, personal history
of benign breast disease, physical activity, alcohol consumption, exogenous hormone use, and breast feeding history. ***All p-interaction with
BMI category were >0.07 except for DMGV p-interaction = 0.04 (simple and adjusted model). ****All p-heterogeneity by ER status were >0.13
except for asparagine p-heterogeneity = 0.02/0.03 (simple/adjusted model).

creatine and C40:7 PE plasmalogen remained statistically signiﬁcant after adjusting for established risk factors and were
selected by at least one multivariable modeling approach (Lasso,
Elastic Net, Random Forests). Notably, associations between 2aminohippuric acid, piperine, and kynurenic acid remained
signiﬁcant even after multiple testing correction. None of the
metabolites showed effect modiﬁcation by BMI, except DMGV.
None of the metabolites showed heterogeneity by ER status,
except asparagine.
Piperine is a polyphenol responsible for the pungency of black
and long pepper and exhibits a wide range of properties: antidiabetic, anti-inﬂammatory, immunomodulatory, reduction of
insulin resistance, and enhanced drug bioavailability24–26. Piperine
also inhibits tumorigenesis, tumor angiogenesis, cancer cell
proliferation, cancer cell migration and invasion, and enhances
apoptosis and autophagy27. Experimental and cell line studies
identiﬁed anti-breast cancer speciﬁc mechanisms of action,
including decreased matrix metalloproteinase 9 (MMP-9) and
MMP-13 expression, induced apoptosis through activation of
caspase-3 and inhibition of human epidermal growth factor
receptor 2 (HER2) gene expression28. Synergetic effects of piperine
Published in partnership with the Breast Cancer Research Foundation

and chemotherapy drugs (paclitaxel, doxorubicin), hormone
therapy drugs (tamoxifen), radiotherapy, TRAIL-based and nanodelivery-based therapy drugs (paclitaxel, rapamycine) were
observed28. Notably, piperine inhibited growth and motility29,
and enhanced efﬁcacy of TRAIL-based therapy30 in triple-negative
breast cancer cells, the most aggressive breast cancer subtype. In
a previous study of the associations of diet-related metabolites
and breast cancer risk within the Prostate, Lung, Colorectal and
Ovarian (PLCO) Cancer screening trial (n = 1242, 621 cases),
piperine was found to be modestly correlated with liquor
consumption (correlation = 0.16) and similar to our study,
inversely associated with breast cancer risk (OR comparing 90th
versus 10th percentile = 0.74 (0.56–0.99, p = 0.045)), after
adjusting for BMI and other potential confounders23. Similarly,
piperine was associated with lower risk of breast cancer (OR per
1 SD increase = 0.94 (0.89–0.99), p = 0.01) in the SU.VI.MAX cohort
(n = 400, 200 cases)20. Notably, PLCO women were postmenopausal while the SU.VI.MAX cohort included premenopausal and
postmenopausal women at the time of blood collection suggesting that the association between piperine and breast cancer may
be independent of menopausal status.
npj Breast Cancer (2021) 54
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Table 2. All metabolites that met q-value < 0.2 (marked as √ in the table) in at least one primary model analysis that adjusts for matching factors
(*marks p-value < 0.05a).
Metabolites

Logisticb

Lassob

DMGV

√*

*

2-aminohippuric acid

√*

piperine
kynurenic acid

√*
√*

√*
*

N2,N2-dimethylguanosine

√*

Phenylacetyl-glutamine

√*

*

C34:3 PC plasmalogen

√*

*

C20:1 LPC

√*

Elastic netb

√*

Random forestb

Number of √

Logisticc

√*

2

*

*

1

√*

√*

4
1

√*
√*

√*
√*

*

√*

√*

Lassoc

Elastic netc

Random forestc
√*
*

*

√*

2
1

*

√*

1

√*

1

C40:7 PE plasmalogen

√*

√*

Asparagine

√*

*

*

Creatine

*

√*

*

*

2

*

1

*

1

*

√*

*

*

*

√*

a

Four metabolites that met threshold for statistical signiﬁcance in Lasso only but had Logistic regression raw p values > 0.3 were excluded (C12:1 carnitine,
C22:5 LPC, C46:2 TAG, glycine)
b
Simple model adjusts for matching factors including menopause status at blood draw, time of blood draw, date/season of blood draw, luteal day at blood
draw, fasting status at blood draw, menopausal status at diagnosis and race
c
Adjusted model: in addition to matching factors, this model adjusts for BMI at age 18, weight change between age 18 and time of blood draw, age at
menarche, parity and age at ﬁrst birth, family history of breast cancer, personal history of benign breast disease, physical activity, alcohol consumption,
exogenous hormone use, and breast feeding history

Table 3.

All metabolites that met q-value < 0.2 in at least one primary model analysis that adjusts for matching factors. M1 is the simple modela
(accounting for matching factors) and M2 is the adjusted modelb (adjusting for matching factors and breast cancer risk factors).
Metabolite
DMGV
2-aminohippuric acid

Model Logistic
odds ratio

Logistic
P-value

Lasso
odds ratio

Lasso
P-value

Elastic net
odds ratio

Elastic net
P-value

Random forest
P-value

M1

0.84

9.23E−05

0.87

4.00E−02

0.90

5.60E−02

<0.01

M2

0.88

1.10E−02

0.89

6.80E−02

0.96

1.64E−01

<0.01

M1

0.84

1.42E−04

0.93

2.24E−01

0.94

2.48E−01

0.02

M2

0.85

7.72E−04

0.92

1.56E−01

0.96

9.60E−02

0.02

Piperine

M1

0.85

4.59E−04

0.80

0.00E+00

0.85

0.00E+00

<0.01

Kynurenic acid

M2
M1

0.84
0.87

2.79E−04
3.00E−03

0.78
0.87

0.00E+00
2.80E−02

0.92
0.90

1.60E−02
5.60E−02

<0.01
0.1

M2

0.86

2.92E−03

0.86

1.20E−02

0.96

8.80E−02

0.11

N2,N2-dimethyl-guanosine M1

0.88

8.47E−03

1.00

1.00E+00

0.97

6.04E−01

<0.01

M2

0.91

6.01E−02

1.00

5.04E−01

0.98

3.04E−01

0.05

M1

0.89

1.15E−02

0.88

2.80E−02

0.90

5.20E−02

0.13

Phenylacetyl-glutamine

M2

0.90

2.13E−02

0.89

2.40E−02

0.96

9.20E−02

0.19

C34:3 PC plasmalogen

M1

1.13

7.64E−03

1.24

2.80E−02

1.09

1.28E−01

0.01

C20:1 LPC

M2
M1

1.09
1.13

7.44E−02
9.00E−03

1.29
1.08

1.60E−02
2.44E−01

1.03
1.06

1.64E−01
3.80E−01

<0.01
0.17

M2

1.10

5.18E−02

1.14

6.00E−02

1.02

2.76E−01

0.25

M1

1.14

3.23E−03

1.25

0.00E+00

1.11

6.80E−02

0.01

M2

1.11

3.01E−02

1.29

0.00E+00

1.03

1.28E−01

0.04

M1

1.14

6.10E−03

1.22

2.80E−02

1.13

3.20E−02

0.02

M2

1.10

5.41E−02

1.18

4.40E−02

1.04

1.20E−01

0.03

M1

1.10

3.94E−02

1.27

0.00E+00

1.16

1.20E−02

0.06

M2

1.13

1.51E−02

1.24

0.00E+00

1.05

5.60E−02

0.07

C40:7 PE plasmalogen
Asparagine
Creatine
a

Simple model: adjusts for matching factors including menopausal status at blood draw, time of blood draw, date/season of blood draw, luteal day at blood
draw, fasting status at blood draw, menopausal status at diagnosis and race
b
Adjusted model: in addition to matching factors, this model adjusts for BMI at age 18, weight change between age 18 and time of blood draw, age at
menarche, parity and age at ﬁrst birth, family history of breast cancer, personal history of benign breast disease, physical activity, alcohol consumption,
exogenous hormone use, breast feeding history
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Fig. 2 Heatmap of all pairwise correlations among the 11
metabolites associated with breast cancer risk. Positive correlations are shown in shades of red while inverse correlations are
shown in shades of blue.

Dimethylguanadino valeric acid (DMGV), an organic keto acid, is
the product of transamination of asymmetric dimethylarginine
(ADMA), which inhibits nitric oxide signaling that is crucial to
endothelial function—excess ADMA is associated with increased
risk of cardiovascular disease31,32. Plasma DMGV is positively
associated with incident coronary artery disease, cardiovascular
mortality, nonalcoholic fatty acid liver disease, and type II
diabetes33,34. Circulating DMGV is directly correlated with resistance to the metabolic beneﬁts of exercise35. Consumption of
vegetables and red wine are associated with lower circulating
DMGV, while sugar-sweetened beverage consumption is associated with higher circulating DMGV34,36. DMGV was associated
with lower breast cancer risk in our study. The association
between DMGV and breast cancer risk has not been previously
assessed in prospective cohort studies. However, this metabolite
was correlated with liver fat in the offspring cohort of the
Framingham Heart Study (β = 0.02, 95% CI: 0.018–0.022, p <
10−23)33. In addition, in the same study, baseline DMGV levels
were associated with higher risk of type 2 diabetes, with
replication of this association in the Malmo Diet and Cancer
study and the Jackson Heart Study33. Large prospective studies are
required to validate the association between DMGV and breast
cancer risk. If replicated, experimental studies will be needed to
understand the complex relationship between DMGV, diet,
physical activity, CVD, type II diabetes, and breast cancer. Of note
is that this analysis was in predominantly premenopausal women,
among whom adiposity is also inversely associated with risk of
breast cancer for reasons that are still not fully understood37.
Although the measurement platform used here was optimized
to measure amino acids and related metabolites, not lipids, our
analysis included a small number of lipids and identiﬁed a few
signiﬁcant associations. Plasmalogens are a subclass of phospholipids (components of the cell membrane and involved in cell
signaling and cell cycle regulation38) that constitute 15–20% of all
phospholipids in cell membranes39. Plasmalogens have head
groups that are usually either phosphatidylcholine (PC plasmalogens) or ethanolamine (PE plasmalogens), and are characterized
by an ether bond to an alkenyl group in the sn-1 position while
the sn-2 position is usually occupied by polyunsaturated fatty
acids39. Certain cancers exhibit altered plasmalogen levels:
circulating plasmalogens are depressed in pancreatic cancer
patients40 and increased in gastric carcinoma patients41 compared
Published in partnership with the Breast Cancer Research Foundation

to healthy controls. Our study identiﬁed two plasmalogens, C34:3
PC plasmalogen and C40:7 PE plasmalogen, associated with
increased risk of breast cancer. The fatty acid component of
speciﬁc lipids may also reﬂect dietary or metabolic processes;
notably C40:7 PE plasmalogen is highly unsaturated but the
position of the double bonds cannot be determined in this
metabolomics assay. Among 74 women with breast cancer, the
levels of the majority of measured phospholipids (LPC, LPE, PC,
and PE) were higher in tumor tissue when compared to normal
breast tissue samples38. Similar trends were observed in another
study comparing tumor to normal tissue in 257 participants with
breast cancer, and these lipids were correlated with cancer
progression and patient survival42. Contrary to our ﬁndings, in the
European Prospective Investigation into Cancer (EPIC) cohort, PC
plasmalogens, including C34:3 PC plasmalogen, were inversely
associated with risk of breast cancer18,19. However, neither study
stratiﬁed their results by menopausal status, thus making a direct
comparison difﬁcult. Additional studies are needed to evaluate
how plasmalogens are associated with risk of breast cancer and if
this relationship is modulated by menopausal status.
LPCs are derived from phosphatidylcholines after hydrolysis of
one of the fatty acid groups. In the liver, LPCs upregulate genes
involved in cholesterol biosynthesis, while circulating LPCs
activate many inﬂammatory and oxidative stress signaling pathways, and are associated with inﬂammatory diseases such as
atherosclerosis and multiple sclerosis43. Circulating LPCs have
mixed associations with certain cancers. For instance, circulating
LPCs are elevated in ovarian cancer patients but depressed in
leukemia patients relative to healthy controls44; LPCs showed
inverse associations with risk of endometrioid and clear cell
ovarian tumors, with stronger inverse associations among
premenopausal women, in NHS and NHSII15,16. While most LPCs
measured in EPIC were inversely associated with risk, one of our
top hits was LPC C20:1 that was positively associated with risk18. In
an earlier study nested within the EPIC cohort of 774 participants
including 362 breast cancer cases, C18:0 LPC was identiﬁed as
inversely associated with breast cancer risk, after adjusting for
potential risk factors19, though analyses were not stratiﬁed by
menopausal status.
Our study identiﬁed three amino acid derivatives associated
with breast cancer risk. High levels of phenylacetylglutamine were
associated with decreased breast cancer risk while high levels of
asparagine and creatine were associated with increased risk.
Phenylacetylglutamine is formed from phenylacetate and glutamine and is found as a normal constituent of human urine45.
Phenylacetylglutamine is a host microbiome cometabolite associated with bacterial phenylalanine metabolism46–49. Clostridium
difﬁcile, F. prausnitzii, Biﬁdobacterium, Subdoligranulum, and
Lactobacillus are all positively associated with hippuric acid48,50,
while Biﬁdobacterium is positively associated with phenylacetylglutamine and microbes of the Christensellaceae, Ruminococcaceae, and Lachnospiracaea families are negatively associated with
phenylacetylglutamine47,51. While not directly linked to breast
cancer risk, high serum levels of phenylacetylglutamine is a
potential early marker of kidney dysfunction in chronic kidney
disease51. Glutamine, a precursor to phenylacetylglutamine, has
been associated with breast cancer risk in a nested case-control
study within the French SU.VI.MAX cohort (n = 211 cases). High
levels of glutamine were associated with increased risk (OR per SD
increase =1.33, 95% CI: 1.07–1.66) and this association persisted
among the subgroup of premenopausal women (p for interaction
= 0.003)52. Notably, elevated expression of asparagine synthetase
correlates with lung metastasis in breast cancer patients53.
Furthermore, in vitro breast cancer studies show asparagine
bioavailability promotes invasion and metastasis and that this
effect is prevented by limiting asparagine bioavailability53. In a
nested case-control study within the EPIC cohort (n = 1624 cases),
asparagine was inversely associated with breast cancer risk (OR =
npj Breast Cancer (2021) 54
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0.87 per SD increase, 95% CI: 0.80–0.95, FDR p = 0.06), in contrast
to the direction of association in our study18. However, the EPIC
study participants were overwhelmingly (> 70%) postmenopausal
at the time of blood collection, in contrast to our population with
80% premenopausal women. Differences in the menopausal
status may partially explain the observed opposite directions of
association between asparagine and breast cancer risk.
Creatine is obtained from meat consumption and synthesized
endogenously from arginine, glycine, and methionine. Most
creatine is found in skeletal muscle, and a signiﬁcant amount is
also found in the brain. Omnivores obtain roughly 50% of their
daily creatine from meat and 50% is biosynthesized, while
vegetarians biosynthesize most of their creatine54 and have
signiﬁcantly lower muscular creatine levels than meat eaters55.
Creatine is broken down to creatinine in a ﬁrst-order reaction, the
rate of which decreases with age and decreased muscle mass56.
Creatine/creatinine metabolism plays an important role in energy
metabolism in skeletal muscle tissue, and thus disturbances in this
pathway are associated with many muscle diseases, whether as a
cause or consequence57. To the best of our knowledge, no
previous work has reported a link between creatine and breast
cancer risk. However, the association we observed in this analysis
is consistent with the positive association between red meat and
risk of breast cancer among premenopausal women in the NHSII
cohort58.
Kynurenic acid and 2-aminohippuric acid are benzenoids
inversely associated with breast cancer risk in our study. 2amminohippuric acid is a glycine conjugate of anthranilic acid and
can be synthesized in the liver59, but little is known about its
biological function. Both kynurenic acid and 2-aminohippuric acid
are part of the kynurenine branch of the tryptophan pathway, an
essential amino acid and a precursor to many biologically active
metabolites60,61. Studies of the function of kynurenic acid suggest
pleiotropic roles in disease. On the one hand, kynurenic acid has
been shown to have anti-inﬂammatory and anti-ulcerative
properties in animal models, as well as antioxidative properties
in vitro in human cells62. On the other hand, circulating kynurenic
acid was associated with increased risk of insulin resistance63.
Kynurenic acid acts as both an anti-inﬂammatory and immunosuppressive factor which in turn allows tumor proliferation64.
Tryptophan metabolism plays an important role in tumor
progression and malignancy with several cancers expressing
tryptophan-degrading enzymes such as IDO165,66. However, the
direct role of kynurenic acid remains unclear, with both
proliferative and antiproliferative effects on human glioblastoma
cells, an antiproliferative effect on human colon adenocarcinoma
cells, and decreased DNA synthesis and inhibited migration in
both cell types62. Neither kynurenic acid nor 2-aminohippuric acid
have been previously associated with breast cancer risk.
N2,N2-dimethylguanosine (DMGU) is a purine nucleoside and a
primary degradation product of transport RNA. Elevated circulating DMGU levels may indicate cellular stress and is associated with
several diseases, including pulmonary arterial hypertension67,
solid tumors68, incident type II diabetes69, and all-cause mortality70. Elevated levels of N2,N2-dimethylguanosine were found in
patients with acute leukemia and breast cancer71. Elevated
circulating levels of this metabolite are associated with lower risk
of breast cancer in our study.
Importantly, there are several studies suggesting lifestyle and
dietary changes may impact circulating levels of the here
identiﬁed metabolites; however, the relationships are complex
and warrant further study. For example, vegetables intake was
positively associated with piperine (manuscript in preparation)
and inversely associated with DMGV34 but both metabolites are
inversely associated with risk. The Mediterranean diet was
positively associated with C40:7 PE plasmalogen72 though this
metabolite was positively associated with risk. Further, physical
activity is inversely associated with creatine and positively
npj Breast Cancer (2021) 54

associated with asparagine73 though we observed positive
associations with breast cancer risk for both metabolites. This
work supports the fact that these metabolites are potentially
modiﬁable, however the complex relationships with breast cancer
risk preclude clear recommendations and more investigation is
required.
Our study has several strengths and limitations. Notably, we
conducted a prospective analysis of amino acid and amino acidrelated metabolomics and risk of breast cancer among a large
number of predominantly premenopausal women. We had
detailed information on sample collection characteristics and risk
factors, which we included in our statistical approaches. Although
metabolomics was measured at only one point in time, the
identiﬁed metabolites are reasonably stable over time74 (ICCs or
correlation over 1–2 years ≥0.75 for nine metabolites; no data are
available for 2-aminohippuric acid and C20:1 LPC). Our cohort
consisted of registered nurses, a group that are not representative
of the general population (e.g., social economic status), however
there is no evidence suggesting that breast carcinogenesis is
different in this group of women. Additionally, our cohort also
included predominantly Caucasian women. However, while the
prevalence of risk factors often differs across population
subgroups, many breast cancer risk factors have been documented to operate similarly across ethnic groups, as would be
expected from a common underlying biology75–88. Nonetheless, it
is crucial that future studies conduct similar analyses in racially
and ethnically diverse cohorts. While we had reasonable power in
most of our analyses, we had limited power among ER negative
tumors. Lastly, the uniqueness of our data measured among
predominantly premenopausal women make replication studies
challenging. We conducted this analysis in a hypothesis generating framework and hope that other cohorts will follow and analyze
metabolomics data stratifying by menopausal status.
In summary, we identiﬁed eleven metabolites associated with
risk of breast cancer among premenopausal women. Seven
metabolites remained associated after adjustment for established
risk factors and were selected by at least one multivariable
modeling approach: higher levels of 2-aminohippuric acid,
kynurenic acid, piperine, DMGV and phenylacetylglutamine were
associated with lower breast cancer risk while higher levels of
creatine and C40:7 PE plasmalogen were associated with
increased breast cancer risk. Additional prospective cohort studies
are needed to assess these associations considering menopausal
status. If these ﬁndings are validated, experimental studies are
warranted to understand the underlying biological mechanisms
driving changes in metabolite levels.
METHODS
Study population
In 1989, 116,429 female registered nurses aged 25–42 y returned a mailed
questionnaire and were enrolled in the NHSII. Participants have been
followed biennially since 1989 with questionnaires collecting information
on reproductive history, lifestyle factors, diet, medication use, and new
disease diagnoses.
In 1996–1999, 29,611 NHSII participants aged 32–54 y contributed blood
samples, as previously described89. Of these, 18,521 women who had not
used oral contraceptives, been pregnant or breastfed in the previous
6 months provided samples timed within the menstrual cycle, targeting
the early follicular (days 3–5 of the cycle) and mid-luteal (7–9 days prior to
expected start of next cycle) phases. The remaining women donated a
single untimed sample. Follicular plasma was separated and frozen by the
participants and returned with the luteal sample; samples were collected
and shipped overnight to our laboratory where we processed and archived
aliquots of white blood cell, red blood cell, and plasma in liquid nitrogen
freezers (≤−130 °C). Follow-up in the blood subcohort is high (96%
in 2011).
The study protocol was approved by the institutional review boards of
the Brigham and Women’s Hospital and Harvard T.H. Chan School of Public
Published in partnership with the Breast Cancer Research Foundation
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Health, and those of participating registries as required. The return of the
self-administered questionnaire and blood sample was considered to
imply consent.

Case and control selection
Cases of breast cancer were identiﬁed after blood collection among
women who had no reported cancer (other than nonmelanoma skin).
Thousand and ﬁfty-seven cases (invasive cases n = 780) were diagnosed
between 1999 and 2011. Breast cancer cases were reported by the
participant, which were conﬁrmed by medical record reviews (n = 1015) or
verbally by the nurse (n = 42). Given the high conﬁrmation rate by medical
record for breast cancer in this cohort (99%), all cases are included in this
analysis.
One control was matched per case by the following factors: age (+/−
2 y), menopausal status and postmenopausal hormone therapy (HT) use at
blood collection and diagnosis (premenopausal, postmenopausal and not
taking HT, postmenopausal and taking HT, and unknown), and month
(+/− 1 month), time of day (+/− 2 h), fasting status at blood collection
(≤8h after a meal or unknown; >8h), race/ethnicity (African–American,
Asian, Hispanic, Caucasian, other) and luteal day (+/− 1 day; timed
samples only).

Covariate information
Data on breast cancer risk factors, including anthropometric measures,
reproductive history, and lifestyle factors, were collected from questionnaires administered biennially and at the time of blood collections. Case
characteristics, including invasive vs. in situ, histologic grade, estrogen and
progesterone receptor (ER, PR), were extracted from pathology reports. As
previously described90, immunohistochemical results for ER and PR, read
manually by a study pathologist, were included for cases with available
tumor tissue included in tissue microarrays.

Laboratory assay
Plasma metabolites were proﬁled at the Broad Institute of MIT and Harvard
(Cambridge, MA) using a liquid chromatography tandem mass spectrometry (LC-MS) method designed to measure polar metabolites such as
amino acids, amino acids derivatives, dipeptides, and other cationic
metabolites as described previously33,74,91,92. Pooled plasma reference
samples were included every 20 samples and results were standardized
using the ratio of the value of the sample to the value of the nearest
pooled reference multiplied by the median of all reference values for the
metabolite. Samples were run together, with matched case-control pairs
(as sets) distributed randomly within the batch, and the order of the case
and controls within each pair randomly assigned. Therefore, the case and
its control were always directly adjacent to each other in the analytic run,
thereby limiting variability in platform performance across matched
case–control pairs. In addition, 238 quality control (QC) samples, to which
the laboratory was blinded, were also proﬁled. These were randomly
distributed among the participants’ samples.
Hydrophilic interaction liquid chromatography (HILIC) analyses of water
soluble metabolites in the positive ionization mode were conducted using
an LC-MS system comprised of a Shimadzu Nexera X2 U-HPLC (Shimadzu
Corp.; Marlborough, MA) coupled to a Q Exactive mass spectrometer
(Thermo Fisher Scientiﬁc; Waltham, MA). Metabolites were extracted from
plasma (10 µL) using 90 µL of acetonitrile/methanol/formic acid
(74.9:24.9:0.2 v/v/v) containing stable isotope-labeled internal standards
(valine-d8, Sigma-Aldrich; St. Louis, MO; and phenylalanine-d8, Cambridge
Isotope Laboratories; Andover, MA). The samples were centrifuged (10 min,
9000 × g, 4 °C), and the supernatants were injected directly onto a 150 ×
2 mm, 3 µm Atlantis HILIC column (Waters; Milford, MA). The column was
eluted isocratically at a ﬂow rate of 250 µL/min with 5% mobile phase A
(10 mM ammonium formate and 0.1% formic acid in water) for 0.5 min
followed by a linear gradient to 40% mobile phase B (acetonitrile with 0.1%
formic acid) over 10 min. MS analyses were carried out using electrospray
ionization in the positive ion mode using full scan analysis over 70–800 m/z
at 70,000 resolution and 3 Hz data acquisition rate. Other MS settings were:
sheath gas 40, sweep gas 2, spray voltage 3.5 kV, capillary temperature
350 °C, S-lens RF 40, heater temperature 300 °C, microscans 1, automatic
gain control target 1e6, and maximum ion time 250 ms. Metabolite
identities were conﬁrmed using authentic reference standards or reference
samples.
In total, 259 known metabolites were measured in this study.
Metabolites not passing our previously conducted processing delay pilot
Published in partnership with the Breast Cancer Research Foundation

study74 were excluded from this analysis (N = 33). All metabolites (N = 226)
included here exhibited good reproducibility within person over 1-2
years74. Two hundred and six metabolites had no missing values among
participant samples. One metabolite had <10% missing values and 19
metabolites had ≥10% missing values. Most of the metabolites (N = 191)
had a coefﬁcient of variation (CV) < 25% and an intraclass correlation
coefﬁcient (ICC) > 0.4 among blinded QC samples. Twenty-ﬁve metabolites
had CV ≥ 25%, ﬁve had ICCs ≤ 0.4, and ﬁve metabolites had CV ≥ 25% and
ICC ≤ 0.4.

Statistical analysis
Metabolite levels were natural logarithm transformed and standardized
prior to statistical analysis. Missing values were imputed by one half the
lowest observed value per metabolite, for metabolites with <10% missing
values (N = 1). Metabolites with >10% missing values (N = 19) were
excluded from the main analysis and evaluated in an exploratory analysis.
Association of metabolite levels with breast cancer risk was assessed in
metabolite-by-metabolite models and in multivariable analyses that
included all metabolites simultaneously.
The association of individual metabolites with breast cancer risk was
assessed in conditional logistic regression models (1057 cases and 1057
controls). In a simple model, each metabolite was included without
adjustment for other factors. In an adjusted model, the following
additional factors were included: BMI at age 18, weight change from age
18 to time of blood draw, age at menarche, parity and age at ﬁrst birth,
family history of breast cancer, diagnosis of benign breast disease, physical
activity, alcohol consumption, exogenous hormone use and breastfeeding
history. Odds ratios (OR) and 95% conﬁdence intervals (95% CI) were
estimated for a one-unit (one standard deviation) increase in the logtransformed and standardized metabolites levels.
We performed analyses restricting to premenopausal women at blood
collection (838 cases and 838 controls), and analyses stratiﬁed by BMI
(<25 kg/m2 [635 cases and 578 controls]; ≥25 kg/m2 [422 cases and 479
controls]) and ER status (ER+ [585 cases and 1057 controls]; ER− [126 cases
and 1057 controls]). In a sensitivity analysis, we observed similar results
between conditional logistic regression and unconditional logistic regression adjusting for the matching factors. Thus, stratiﬁed analyses were
conducted using unconditional logistic regression, additionally adjusting
for the matching factors. To test for effect modiﬁcations by BMI and
heterogeneity by ER status, we included cross-product terms of the
metabolite with potential effect modiﬁer in conditional logistic models and
report the p-value for that interaction. As ER status represents a case
characteristic, we assigned each control the ER status of its matched case.
In an exploratory analysis we assessed the association with risk of breast
cancer for the 19 metabolites with >10% missing values. We included the
continuous metabolite level as well as a presence/absence indicator in the
fully adjusted conditional logistic regression model and performed a
likelihood-ratio test (full model compared to a model excluding both the
metabolite and the presence/absence indicator) to estimate the signiﬁcance level of the association.
Multivariable analyses evaluating the joint association of the 207
metabolites with breast cancer risk were based on (1) conditional logistic
regression with lasso penalty (“Lasso”), (2) conditional logistic regression
with an elastic net penalty (“Elastic Net”), and (3) random forests. In the
Lasso and Elastic Net analyses, a minimally adjusted model included only
the set of 207 metabolites, whereas a fully adjusted model further adjusted
for the risk factors noted above. In each analysis, the optimal values of the
regularization parameter(s) were estimated as that which minimizes the
average deviance in the left-out partitions, in a 10-fold cross validation
procedure. A p-value for each metabolite was obtained from a permutation
test in which the case/control labels were permuted within each matched
stratum. A p-value for each metabolite was calculated as the proportion of
permutations (out of 250) in which the magnitude of the coefﬁcient under
label permutation was at least as large as the regression coefﬁcient in the
observed dataset. Analyses were carried out using the R library clogitL193.
Random forests analyses included a minimally adjusted model that
included the 207 metabolites and matching factors. A fully adjusted model
also included the additional risk factors noted above. In all analyses, the
parameter mtry corresponding to the number of variables randomly
sampled as candidates at each split was set to the square root of the total
number of covariates in the model. Each classiﬁer was an aggregate of
5000 trees. A p-value for each metabolite was obtained from a permutation
test as described above in which the case/control labels were randomly
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permuted 100 times. Analyses were carried out using the R library random
forests94.
To adjust for multiple testing in the conditional logistic regression and
the multivariable models we estimated the positive FDR based on the qvalue procedure95. Metabolites that satisﬁed a p-value less than 0.05 and
corresponding q-value less than 0.20 in the minimally adjusted model were
discussed as primary ﬁndings.
Criterion for statistical signiﬁcance: metabolites that met a p-value < 0.05
and q-value < 0.20 in at least one of the four models (Conditional Logistic
Regression, Lasso, Elastic Net, and Random Forests) with minimal
adjustment were considered as statistically signiﬁcant. An exception was
made for metabolites that did not meet a p-value threshold < 0.05 in the
conditional logistic regression: four metabolites that met the threshold for
statistical signiﬁcance in Lasso only but had high raw p-values (>0.3) in the
conditional logistic regression were excluded (C12:1 carnitine, C22:5 LPC,
C46:2 TAG, glycine).
A metabolite score was estimated for each participant as a linear
combination of all metabolites that met the threshold for statistical
signiﬁcance. The coefﬁcients associated with each metabolite were
estimated in a conditional logistic regression model with the Lasso
penalty that included all metabolites simultaneously and with full
adjustment for all potential confounders.
Analyses were caried out using R96 version 3.6.3 and SAS version 9.4. All
statistical tests were two-sided.

Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.

DATA AVAILABILITY
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research participant privacy. Requests to access these data should be made via http://
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